Exploratory, open clinical study (International Pharmacopsychiatry 1973; Grof S, Soskin RA, Richards WA, Kurland AA; Spring Grove State Hospital, Baltimore, MD, USA). Participants: 51 alcoholic patients drawn from the Alcoholic Rehabilitation Unit of Spring Grove State Hospital, selected by medical and psychiatric screening for suitability for psychedelic-peak therapy. Exclusions included organic brain damage, epilepsy, active renal or hepatic disease, and other specified contraindications. Intervention: dipropyltryptamine (DPT), a synthetic short-acting psychedelic, administered as an adjunct to psychotherapy in a psychedelic-peak therapy framework. No control arm; open-label exploratory design. Outcomes: clinical and psychotherapeutic change in alcoholism. No trial registry; pre-dates any formal registration requirement by ~32 years.
This synthetic trial has been added to our database because a psychedelic paper (about a clinical trial) references this trial, but no (live) registration can be found.
The study investigated the efficacy of dipropyltryptamine (DPT) administered intramuscularly as an adjunct to psychedelic-peak psychotherapy for individuals suffering from alcoholism. Participants were recruited from the Alcoholic Rehabilitation Unit at Spring Grove State Hospital and underwent medical and psychiatric screening to ensure suitability for the intervention.
Outcomes were measured using a comprehensive battery of psychological tests, including the Minnesota Multiphasic Personality Inventory (MMPI) and the Personal Orientation Inventory (POI), alongside assessments of residential, occupational, and interpersonal adjustment. Follow-up evaluations were conducted by an independent team of social workers to monitor abstinence and global adjustment.
High doses of DPT (60-150 mg) administered intramuscularly as an adjunct to psychotherapy.
Dose range 60-150 mg; sessions lasted 4-6 h; average 1.86 sessions per patient.